The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...

Shares of Moderna Inc. fell over 8% on Wednesday afternoon, paring some of the gains from Tuesday, the stock’s best trading ...

The stock's fall snapped a five-day winning streak.

The Covid-19 positivity rate has also seen a rise to 7.1% this past week, versus the 5.5% figure for the past four weeks.

Moderna stock was on track to see a weekly gain of 10% as of Wednesday following the first reported bird flu death in the US.

In absolute dollar amount, the Cambridge drugmaker had the biggest drop in market cap among any public Massachusetts company ...

Moderna surged as investors turned eyed potential demand for a vaccine to protect against bird flu after the US reported its ...

With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Moderna shares soared as investors placed bets that the pharmaceutical giant’s development of an H5N1 bird flu vaccine could ...

Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

UBS lowered the firm’s price target on Moderna (MRNA) to $96 from $108 and keeps a Buy rating on the shares as part of a broader note on the ...